Advertisement
Advertisement
EWTX
Edgewise Therapeutics, Inc. Common Stock
40.03
USDSponsored
+1.92
+5.04%
Nov 03, 11:23 UTC -5
Open
Edgewise Therapeutics, Inc. Common Stock (EWTX) Earnings
EWTX Earnings Reports
Positive Surprise Ratio
EWTX beat 14 of 22 last estimates.
64%
Next Report
In 2 Days
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/$2.53
Implied change from Q2 26 (Revenue/ EPS)
--
/-577.36%
Implied change from Q3 25 (Revenue/ EPS)
--
/-748.72%
Edgewise Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, EWTX reported earnings of -0.53 USD per share (EPS) for Q2 26, missing the estimate of -0.47 USD, resulting in a -10.55% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.27% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of 2.53 USD, with revenue projected to reach -- USD, implying an decrease of -577.36% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alkermes Inc. plc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.07
Actual
$0.09
Surprise
+225.00%
Rhythm Pharmaceuticals, Inc. Common Stock
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+15.83%
Travere Therapeutics, Inc. Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.05
Actual
-$0.55
Surprise
-846.64%
Recursion Pharmaceuticals, Inc. Class A Common Stock
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.23
Actual
-$0.22
Surprise
+5.54%
Vertex Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$4.88
Actual
$4.76
Surprise
-2.51%
BioNTech SE - ADR
Report Date
Nov 03, 2026 For Q3 26
Estimate
$0.80
Actual
$1.81
Surprise
+126.53%
Jazz Pharmaceuticals, Inc.
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$3.93
Actual
-$3.88
Surprise
+1.38%
BioMarin Pharmaceuticals Inc
Report Date
Nov 02, 2026 For Q3 26
Estimate
$0.12
Actual
$0.23
Surprise
+89.77%
Arvinas, Inc
Report Date
Nov 03, 2026 For Q3 26
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.71%
Emergent Biosolutions, Inc.
Report Date
Nov 02, 2026 For Q3 26
Estimate
-$0.39
Actual
-$0.36
Surprise
+8.61%
FAQ
What were Edgewise Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Edgewise Therapeutics, Inc. Common Stock reported EPS of -$0.53, missing estimates by -10.55%, and revenue of $0.00, 0% as expectations.
How did the market react to Edgewise Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -1.27%, changed from $44.99 before the earnings release to $44.42 the day after.
When is Edgewise Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Edgewise Therapeutics, Inc. Common Stock's next earnings report?
Based on --
analysts, Edgewise Therapeutics, Inc. Common Stock is expected to report EPS of $2.53 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.